Layla M. Parast, Ph.D.
Affiliations: | 2012 | Biostatistics | Harvard University, Cambridge, MA, United States |
Area:
Biostatistics Biology, EpidemiologyGoogle:
"Layla Parast"Parents
Sign in to add mentor| Tianxi Cai | grad student | 2012 | Harvard | |
| (Landmark Prediction of Survival.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Parast L, Cai T, Tian L. (2024) A rank-based approach to evaluate a surrogate marker in a small sample setting. Biometrics. 80 |
| Parast L, Tian L, Cai T, et al. (2023) Statistical Methods to Evaluate Surrogate Markers. Medical Care |
| Parast L, Tian L, Wei LJ. (2023) Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck. Jama Oncology |
| Parast L, Tian L, Cai T, et al. (2023) Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers. Bmj Open Diabetes Research & Care. 11 |
| Parast L, Cai T, Tian L. (2022) Using a surrogate with heterogeneous utility to test for a treatment effect. Statistics in Medicine |
| Agniel D, Hejblum BP, Thiébaut R, et al. (2022) Doubly robust evaluation of high-dimensional surrogate markers. Biostatistics (Oxford, England) |
| Wang X, Parast L, Han L, et al. (2022) Robust approach to combining multiple markers to improve surrogacy. Biometrics |
| Zhou RR, Zhao SD, Parast L. (2022) Estimation of the proportion of treatment effect explained by a high-dimensional surrogate. Statistics in Medicine |
| Parast L, Cai T, Tian L. (2021) Testing for heterogeneity in the utility of a surrogate marker. Biometrics |
| Wang X, Cai T, Tian L, et al. (2021) Quantifying the feasibility of shortening clinical trial duration using surrogate markers. Statistics in Medicine |